{"filing":{"accession_number":"0001104659-26-072980","cik":"0001818382","ticker":"HUMAW","company_name":"Humacyte, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"tm2617224d2_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1818382/000110465926072980/tm2617224d2_8k.htm"},"events":[{"id":5303,"run_id":4647,"accession_number":"0001104659-26-072980","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Humacyte entered into an underwriting agreement on June 10, 2026 to issue and sell 47,619,048 shares of common stock at $1.05 per share in a registered public offering, with a 30-day option for up to an additional 7,142,857 shares. The offering is expected to raise approximately $46.80 million (or $53.85 million with full option exercise), representing a substantial dilutive issuance to existing shareholders.","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6384,"accession_number":"0001104659-26-072980","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Humacyte entered into an underwriting agreement on June 10, 2026 to issue and sell 47,619,048 shares of common stock at $1.05 per share, with an additional 30-day option for up to 7,142,857 shares. This is a registered public offering of equity securities expected to raise approximately $46.80 million (or $53.85 million with full option exercise), representing a substantial dilutive issuance that would materially affect existing shareholders' ownership percentages and is therefore material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:44:13.283376+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6385,"accession_number":"0001104659-26-072980","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses commencement and pricing of an offering by Humacyte, Inc. on June 10, 2026. While the specific terms are not detailed in this Item 7.01 excerpt, the announcement of an offering's commencement and pricing is a material capital-raising event that would dilute existing shareholders. This is consistent with dilutive issuance disclosure, typically involving equity or convertible securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:44:13.283376+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6384,"accession_number":"0001104659-26-072980","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Humacyte entered into an underwriting agreement on June 10, 2026 to issue and sell 47,619,048 shares of common stock at $1.05 per share, with an additional 30-day option for up to 7,142,857 shares. This is a registered public offering of equity securities expected to raise approximately $46.80 million (or $53.85 million with full option exercise), representing a substantial dilutive issuance that would materially affect existing shareholders' ownership percentages and is therefore material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:44:13.283376+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-11"},{"id":6385,"accession_number":"0001104659-26-072980","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses commencement and pricing of an offering by Humacyte, Inc. on June 10, 2026. While the specific terms are not detailed in this Item 7.01 excerpt, the announcement of an offering's commencement and pricing is a material capital-raising event that would dilute existing shareholders. This is consistent with dilutive issuance disclosure, typically involving equity or convertible securities.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:44:13.283376+00:00","company_name":"Humacyte, Inc.","ticker":"HUMAW","filing_date":"2026-06-11"}]}